

Armando Orlandi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/121338/publications.pdf>

Version: 2024-02-01

105
papers

1,549
citations

393982

19
h-index

344852

36
g-index

107
all docs

107
docs citations

107
times ranked

3174
citing authors

#	ARTICLE	IF	CITATIONS
1	Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 353-361.	5.1	63
2	Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies. <i>Cancers</i> , 2022, 14, 1052.	1.7	2
3	Level II Oncoplastic Surgery as an Alternative Option to Mastectomy with Immediate Breast Reconstruction in the Neoadjuvant Setting: A Multidisciplinary Single Center Experience. <i>Cancers</i> , 2022, 14, 1275.	1.7	6
4	Prognostic Factors in Patients with Breast Cancer Liver Metastases Undergoing Liver Resection: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 1691.	1.7	4
5	PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives. <i>Cancers</i> , 2022, 14, 2161.	1.7	15
6	Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 247-253.	1.1	20
7	Automated breast volume scanner (ABVS) compared to handheld ultrasound (HHUS) and contrast-enhanced magnetic resonance imaging (CE-MRI) in the early assessment of breast cancer during neoadjuvant chemotherapy: an emerging role to monitoring tumor response?. <i>Radiologia Medica</i> , 2021, 126, 517-526.	4.7	24
8	Homologous Repair Deficiency Status and Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: The Best Current Biomarker to Select the Most Appropriate Treatment?. <i>Journal of Cancer Science and Clinical Therapeutics</i> , 2021, 05, .	0.2	3
9	CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. <i>Cancers</i> , 2021, 13, 332.	1.7	35
10	Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA. <i>Cancer Biology and Medicine</i> , 2021, 18, 875-887.	1.4	7
11	Immediate Prosthetic Breast Reconstruction after Nipple-Sparing Mastectomy: Traditional Subpectoral Technique versus Direct-to-Implant Prepectoral Reconstruction without Acellular Dermal Matrix. <i>Journal of Personalized Medicine</i> , 2021, 11, 153.	1.1	25
12	Sentinel Node Biopsy after Neoadjuvant Chemotherapy for Breast Cancer: Preliminary Experience with Clinically Node Negative Patients after Systemic Treatment. <i>Journal of Personalized Medicine</i> , 2021, 11, 172.	1.1	9
13	Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis. <i>Journal of Personalized Medicine</i> , 2021, 11, 187.	1.1	5
14	Development of a Digital Research Assistant for the Management of Patientsâ€™ Enrollment in Oncology Clinical Trials within a Research Hospital. <i>Journal of Personalized Medicine</i> , 2021, 11, 244.	1.1	7
15	Neoadjuvant Chemotherapy in Breast Cancer: An Advanced Personalized Multidisciplinary Prehabilitation Model (APMP-M) to Optimize Outcomes. <i>Journal of Personalized Medicine</i> , 2021, 11, 324.	1.1	9
16	Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study). <i>Cancers</i> , 2021, 13, 2098.	1.7	5
17	Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 11, 100158.	1.3	9
18	How will artificial intelligence impact breast cancer research efficiency?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1067-1070.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Impact on survival of primary tumor resection in patients with metastatic breast cancer: preliminary results of a retrospective analysis. <i>Minerva Surgery</i> , 2021, 76, .	0.1	0
20	Let-7a-5p, miR-100-5p, miR-101-3p, and miR-199a-3p Hyperexpression as Potential Predictive Biomarkers in Early Breast Cancer Patients. <i>Journal of Personalized Medicine</i> , 2021, 11, 816.	1.1	12
21	The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2021, 11, 651723.	1.3	9
22	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598.	1.4	6
23	Poor efficacy of palbociclib in secondâ€line treatment of metastatic lobular breast cancer in a case series: Use before or never more?. <i>Breast Journal</i> , 2020, 26, 1458-1460.	0.4	3
24	Menopausal hormone therapy: What should be kept in mind for a personalized choice in a shared decision-making. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 246, 191-192.	0.5	1
25	Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy. <i>Diagnostic and Interventional Imaging</i> , 2020, 101, 649-655.	1.8	13
26	The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases. <i>Scientific Reports</i> , 2020, 10, 10871.	1.6	10
27	Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Approach and Systemic Therapy in a Guide for Clinicians. <i>Cancers</i> , 2020, 12, 2390.	1.7	21
28	Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2â€ Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series. <i>Journal of Personalized Medicine</i> , 2020, 10, 291.	1.1	4
29	Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Laurenâ€™s Classification in Panâ€™ Cancer Analysis Era?. <i>Cancers</i> , 2020, 12, 1749.	1.7	9
30	OlympiAD trial: moving to a next level of treatment for patients with BRCA mutation and her2-negative metastatic breast cancer. <i>Annals of Palliative Medicine</i> , 2020, 9, 510-511.	0.5	1
31	Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 687-699.	0.9	41
32	Smoking habit and hospitalization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind the evidence.. <i>European Journal of Internal Medicine</i> , 2020, 77, 121-122.	1.0	28
33	Abstract P1-19-43: Palbociclib-fulvestrant (PALBO-FUL) and everolimus -exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis. , 2020, , .		0
34	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the â€™BRAF BeCoolâ€™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	1.3	51
35	Chemotherapy rechallenge or reintroduction, regorafenib, and TAS-102 for metastatic pretreated colorectal cancer patients: a propensity score analysis of treatment beyond the second line (PROSERpINA Study). <i>Annals of Oncology</i> , 2019, 30, iv37-iv38.	0.6	1
36	Clinical, pathological, and prognostic features of rare BRAF mutations in metastatic colorectal cancer: a bi-institutional retrospective analysis (REBUS study). <i>Annals of Oncology</i> , 2019, 30, iv87.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Class 1, 2, and 3 <i>BRAF</i> -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. <i>Clinical Cancer Research</i> , 2019, 25, 3954-3961.	3.2	67
38	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. <i>European Journal of Cancer</i> , 2019, 107, 164-174.	1.3	9
39	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. <i>Journal of Cellular Physiology</i> , 2019, 234, 7708-7717.	2.0	21
40	Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. <i>Pathology and Oncology Research</i> , 2019, 25, 513-520.	0.9	5
41	FOLFOX rechallenge versus regorafenib in patients with metastatic colorectal cancer refractory to standard chemotherapy: A retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 669-669.	0.8	3
42	Abstract B069: Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells. , 2019, , .		0
43	Locally advanced gastric cancer (LAGC): Does histology suggest strategy in PAN-cancer Era?. <i>Journal of Clinical Oncology</i> , 2019, 37, 97-97.	0.8	0
44	The impact of multidisciplinary team (MDT) management on outcome of hepatic resection in liver-limited colorectal metastases.. <i>Journal of Clinical Oncology</i> , 2019, 37, 671-671.	0.8	0
45	Histology could predict a "hot" or a "cold" gastric tumor?. <i>Journal of Clinical Oncology</i> , 2019, 37, 44-44.	0.8	0
46	Clinical, pathological and prognostic features of rare BRAF mutations (MTs) in metastatic colorectal cancer (mCRC): A bi-institutional retrospective analysis (REBUS study).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3554-3554.	0.8	0
47	Chemotherapy rechallenge or reintroduction (CTr/r), regofenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients (pts): A propensity score analysis of treatment beyond second-line (PROSERpINA Study).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3556-3556.	0.8	3
48	Usefulness of automated breast volume scanner (ABVS) for monitoring tumor response to neoadjuvant treatment in breast cancer patients: preliminary results. <i>European Review for Medical and Pharmacological Sciences</i> , 2019, 23, 225-231.	0.5	11
49	Diffuse liver infiltration by lobular breast carcinoma: Shear wave elastography as gold standard imaging study. <i>Breast Journal</i> , 2018, 24, 650-651.	0.4	0
50	Clinico-pathological and molecular characterization of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?. <i>Annals of Oncology</i> , 2018, 29, v58.	0.6	1
51	Phase III study with FOLFIRI+ cetuximab versus FOLFIRI+ cetuximab followed by cetuximab alone in <i>RAS</i> and <i>BRAF</i> WT mCRC. <i>Future Oncology</i> , 2018, 14, 1339-1346.	1.1	5
52	Abstract 5723: Inactivation of DNA repair triggers neoantigen generation and impairs tumor growth. <i>Cancer Research</i> , 2018, 78, 5723-5723.	0.4	5
53	Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?. <i>Journal of Clinical Oncology</i> , 2018, 36, 3590-3590.	0.8	4
54	Diagnosis and management of breast lymphoma: a single-institution retrospective analysis. <i>Translational Cancer Research</i> , 2018, 7, S272-S280.	0.4	2

#	ARTICLE	IF	CITATIONS
55	The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the "unexplainable". Personalized Medicine, 2018, 15, 319-327.	0.8	2
56	To treat or not to treat: HER2 equivocal is the matter!. Translational Cancer Research, 2018, 7, S433-S435.	0.4	0
57	Neutrophil/lymphocyte ratio as surrogate of cetuximab antibody-dependent cell-mediated cytotoxicity in first line metastatic colorectal cancer: A preliminary and exploratory analysis of the ERMES phase III trial.. Journal of Clinical Oncology, 2018, 36, e15656-e15656.	0.8	0
58	Abstract 2743: Accumulation of predicted neoantigens by MMR deficiency triggered by temozolomide treatment of human colorectal cancer. , 2018, , .		0
59	A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. British Journal of Cancer, 2017, 116, 1279-1286.	2.9	37
60	New challenges in multimodal workout of locally advanced breast cancer. Journal of the Royal College of Surgeons of Edinburgh, 2017, 15, 372-378.	0.8	2
61	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature, 2017, 552, 116-120.	13.7	480
62	Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT. Annals of Oncology, 2017, 28, iii95.	0.6	0
63	Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT.. Journal of Clinical Oncology, 2017, 35, 11601-11601.	0.8	1
64	Cetuximab metastatic colorectal cancer strategy (ERMES) study: A phase III randomized two arm study with FOLFIRI + cetuximab until disease progression compared to FOLFIRI + cetuximab for 8 cycles followed by cetuximab alone until disease progression in first-line treatment of patients with RAS and BRAF wild type metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, TPS810-TPS810.	0.8	3
65	IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients. Oncotarget, 2017, 8, 16887-16898.	0.8	28
66	A phase 2 study of temozolomide in patients affected by pretreated metastatic colorectal cancer with MGMT promoter methylation.. Journal of Clinical Oncology, 2017, 35, 629-629.	0.8	1
67	Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility. Anticancer Research, 2017, 37, 6453-6458.	0.5	5
68	Efficacia duratura e ottima tollerabilit� di lapatinib associato a capecitabina metronomica in due pazienti con carcinoma mammario HER2-positivo. AboutOpen, 2017, 3, 112-116.	0.2	0
69	ERCC1 Biomarker in Colorectal Cancer: To Induce or Not to Induce? This Is the Matter!. Oncomedicine, 2016, 1, 25-27.	1.1	3
70	Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases. Medicine (United States), 2016, 95, e3722.	0.4	18
71	LUX-Lung 7: is there enough data for a final conclusion?. Lancet Oncology, The, 2016, 17, e267-e268.	5.1	0
72	Paradox CA 15�3 increase in metastatic breast cancer patients treated with everolimus: a change of paradigm in a case series. Biomarkers in Medicine, 2016, 10, 1191-1195.	0.6	5

#	ARTICLE	IF	CITATIONS
73	Transdermal grisetron for the prevention of chemotherapy-induced nausea and vomiting in metastatic colorectal cancer patients with high risk of bowel obstruction treated with temozolomide. <i>Annals of Oncology</i> , 2016, 27, vi502.	0.6	0
74	Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. <i>Clinical and Translational Oncology</i> , 2016, 18, 988-995.	1.2	16
75	KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 65-74.	1.6	7
76	Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis. <i>Clinical and Translational Oncology</i> , 2016, 18, 40-46.	1.2	13
77	Mastectomy in precision oncology era: myth or reality?. <i>Translational Cancer Research</i> , 2016, 5, S544-S545.	0.4	0
78	2083 Resection of lung metastases from colorectal cancer: Analysis of outcome and prognostic factors. <i>European Journal of Cancer</i> , 2015, 51, S355-S356.	1.3	0
79	2190 Discovery of new molecular subtypes of non-hypermutated metastatic colorectal cancer (mCRC) through a next-generation sequencing (NGS) approach. <i>European Journal of Cancer</i> , 2015, 51, S396-S397.	1.3	0
80	Trastuzumab-induced corneal ulceration: successful no-drug treatment of a "blind" side effect in a case report. <i>BMC Cancer</i> , 2015, 15, 973.	1.1	28
81	ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line<i>: In Vitro</i> Veritas. <i>Journal of Cancer</i> , 2015, 6, 70-81.	1.2	16
82	P-164 Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma HENT1 positive: back to the future. <i>Annals of Oncology</i> , 2015, 26, iv47.	0.6	1
83	BRAF in metastatic colorectal cancer: the future starts now. <i>Pharmacogenomics</i> , 2015, 16, 2069-2081.	0.6	14
84	Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 272-281.	2.0	15
85	Single-Agent Panitumumab in Frail Elderly Patients With Advanced <i>RAS</i> and <i>BRAF</i> Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. <i>Oncologist</i> , 2015, 20, 1261-1265.	1.9	42
86	New life for retrospective study in the precision oncology era. <i>Annals of Oncology</i> , 2015, 26, 2352-2353.	0.6	2
87	AMAROS Study: Overall Survival in Breast Cancer Subtypes. <i>Clinical Oncology</i> , 2015, 27, 485-486.	0.6	4
88	Gemcitabine versus FOLFIRINOX in patients with advanced hENT1^{+ve} pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15295-e15295.	0.8	1
89	DEBIRI and capecitabine in refractory prevalently liver metastases of colorectal cancer: A phase II study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 724-724.	0.8	0
90	K-RAS codon 13 mutation in advanced colorectal cancer: A single-center retrospective study investigating prognostic outcomes and treatment strategies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 633-633.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Pathologic complete response after neoadjuvant chemotherapy as a real surrogate endpoint of outcome for all breast cancer subtypes? Results of a single institution experience.. Journal of Clinical Oncology, 2015, 33, e11613-e11613.	0.8	0
92	ERCC1 induction after oxaliplatin exposure may depend on KRAS mutational status in colorectal cancer patient: preliminary data from liquid biopsy.. Journal of Clinical Oncology, 2015, 33, 11033-11033.	0.8	0
93	Resection of lung metastases from colorectal cancer: Analysis of outcome and prognostic factors.. Journal of Clinical Oncology, 2015, 33, e14556-e14556.	0.8	0
94	Potential role of IL-8 and eNOS polymorphisms in the outcome of bevacizumab-treated colorectal cancer patients: an exploratory analysis.. Journal of Clinical Oncology, 2015, 33, e22015-e22015.	0.8	0
95	Targeted Therapy in Advanced Gastric Carcinoma: The Future is Beginning. Current Medicinal Chemistry, 2014, 21, 1026-1038.	1.2	29
96	KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients. British Journal of Cancer, 2013, 108, 115-120.	2.9	30
97	Kras Mutational Status and Oxaliplatin Sensitivity: The Other Side of the Moon?. Annals of Oncology, 2012, 23, ix84-ix85.	0.6	0
98	ERCC1, KRAS mutation, and oxaliplatin sensitivity in colorectal cancer: Old dogs and new tricks.. Journal of Clinical Oncology, 2012, 30, 489-489.	0.8	3
99	New biomarkers to predict response to oxaliplatin-based chemotherapy in metastatic colorectal cancer: KRAS and ERCC1.. Journal of Clinical Oncology, 2012, 30, 500-500.	0.8	2
100	ERCC1, KRAS mutation, redox status, and oxaliplatin sensitivity in colorectal cancer: "Radical" change in an old model.. Journal of Clinical Oncology, 2012, 30, e14156-e14156.	0.8	0
101	Supportive simultaneous care: A novel approach to frail cancer patients.. Journal of Clinical Oncology, 2012, 30, e16553-e16553.	0.8	1
102	Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer?. Clinical Colorectal Cancer, 2011, 10, 325-332.	1.0	78
103	Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Proliferation, 2011, 44, 139-146.	2.4	56
104	Lung adenocarcinoma presenting as a solitary gingival metastasis: a case report. Journal of Medical Case Reports, 2011, 5, 202.	0.4	10
105	A pilot study of neoadjuvant chemotherapy with gemcitabine (GMZ) plus a platinum compound in locally advanced bladder cancer: Preliminary results.. Journal of Clinical Oncology, 2011, 29, e15142-e15142.	0.8	0